The preliminary clinical studies of T-Dxd demonstrated prospective anticancer activity in both HER2-positive and HER2-negative breast cancer patients, with a significant percentage of patients suffering modest to serious side-effects, particularly with T-Dxd allied potential ILD. Here, ERBB2 is linked to breast cancer.